en Oncology Oncology Review Article Review Article <span style="font-size:14px;"><span style="font-family:Times New Roman;">Almost half of cancer patients experience cachexia syndrome. Cachexic patients are at risk of increased side effects of chemotherapy, reduced tolerance to chemotherapy drugs, longer duration of treatment period, and decreased quality of life. Cancer cachexia is a multifactorial syndrome. Micro ribonucleic acid (miRNA), a &ldquo;non-coding RNA&rdquo;, is considered to be a risk factor of cachexia and muscle wasting in cancer patients. miRNA has a role in affecting protein regulation, associated with different inflammatory and disease pathways. miRNA can also affect cytokines or directly change the regulation of metabolism that lead to cachexia. In this review, we want to focus on the pathophysiology to give a better understanding about the role of miRNA in the development of cancer cachexia. Based on various pathways of miRNA in cancer cachexia, it can be a potential target for therapeutic strategies. Improved knowledge about miRNA can give the opportunity to develop new treatment in the management of cancer cachexia.</span></span> micro RNA, cancer, cachexia, muscle wasting 124 128 http://caspjim.com/browse.php?a_code=A-10-1485-2&slc_lang=en&sid=1 Noorwati Sutandyo noorwatisoetandyo@gmail.com 100319475328460028129 100319475328460028129 Yes Hematology and Medical Oncology Division, Dharmais National Cancer Centre Hospital, Jakarta, Indonesia